IFN alpha in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
2.45 [0.21 ; 28.37 ] Pandit, 2021, Shashi Bhushan, 2021 2 0% 289 moderate not evaluable deathsdetailed results Li, 2021 (REV) 0.96 [0.02; 49.30]
Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
1.89 [0.24 ; 15.10 ] Li, 2021 (REV), Pandit, 2021, Shashi Bhushan, 2021 3 0% 383 moderate not evaluable clinical deteriorationdetailed results Li, 2021 (REV) 1.94 [0.06; 59.14]
1.94 [0.06 ; 59.14 ] Li, 2021 (REV) 1 0% 94 NA not evaluable clinical improvementdetailed results Li, 2021 (REV) 0.57 [0.36; 0.91]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
0.58 [0.38 ; 0.90 ] Li, 2021 (REV), Shashi Bhushan, 2021 2 0% 338 moderate not evaluable clinical improvement (14-day)detailed results Li, 2021 (REV) 0.35 [0.15; 0.81]
Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
0.91 [0.22 ; 3.74 ] Li, 2021 (REV), Pandit, 2021, Shashi Bhushan, 2021 3 72% 375 moderate not evaluable clinical improvement (28-day)detailed results Li, 2021 (REV) 0.23 [0.06; 0.91]
0.23 [0.06 ; 0.91 ] Li, 2021 (REV) 1 0% 94 NA not evaluable clinical improvement (7-day)detailed results Li, 2021 (REV) 0.55 [0.12; 2.43]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.24 [0.39 ; 3.97 ] Li, 2021 (REV), Shashi Bhushan, 2021 2 57% 316 moderate not evaluable clinical improvement (time to event analysis only)detailed results Li, 2021 (REV) 0.57 [0.36; 0.91]
0.57 [0.36 ; 0.91 ] Li, 2021 (REV) 1 0% 96 NA not evaluable mechanical ventilationdetailed results Li, 2021 (REV) 1.94 [0.06; 59.14]
1.94 [0.06 ; 59.14 ] Li, 2021 (REV) 1 0% 94 NA not evaluable viral clearance detailed results Li, 2021 (REV) 0.13 [0.02; 1.10]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.27 [0.29 ; 5.51 ] Li, 2021 (REV), Pandit, 2021, Shashi Bhushan, 2021 3 72% 375 moderate not evaluable viral clearance (time to event analysis only)detailed results Li, 2021 (REV) 0.57 [0.36; 0.91]
0.57 [0.36 ; 0.91 ] Li, 2021 (REV) 1 0% 96 NA not evaluable viral clearance by day 14detailed results Li, 2021 (REV) 0.57 [0.23; 1.41]
Pandit, 2021 10.23 [1.12; 93.35]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.25 [0.00 ; 17.44 ] Li, 2021 (REV), Pandit, 2021, Shashi Bhushan, 2021 3 97% 1,453 moderate not evaluable viral clearance by day 7detailed results Li, 2021 (REV) 0.45 [0.20; 1.05]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.40 [0.39 ; 5.02 ] Li, 2021 (REV), Pandit, 2021, Shashi Bhushan, 2021 3 83% 375 moderate not evaluable serious adverse eventsdetailed results Pandit, 2021 0.95 [0.02; 50.33]
0.95 [0.02 ; 50.33 ] Pandit, 2021 1 0% 39 NA not evaluable adverse eventsdetailed results Pandit, 2021 1.68 [0.47; 5.97]
1.68 [0.47 ; 5.97 ] Pandit, 2021 1 0% 39 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 20:30 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 899,1235
- roots T: 290
